Veronica Finisguerra
- Immunology top 5%
- Immune cells in cancer 2
- Phagocytosis and Immune Regulation 2
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 3
- Oncology top 10%
- Cancer Cells and Metastasis 4
- Hepatology top 10%
- Liver physiology and pathology 2
-
- Axon Guidance and Neuronal Signaling 3
-
- Hippo pathway signaling and YAP/TAZ 3
-
- Cancer-related gene regulation 2
- Co-authors
- Massimiliano MazzoneAndrea CasazzaGiusy Di ConzaSofie DeschoemaekerHans PrenenMathias WenesSarah R. WalmsleyZvi Granot
- Cited by
- ImmunologyCancer ResearchOncology
- Journals
- Nature (1 paper)Journal of Clinical Investigation (3 papers)Nature Communications (2 papers)
- Partner nations
- BelgiumItalyUnited Kingdom
In The Last Decade
Veronica Finisguerra
13 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 83
- Immunology 443
- Cancer Research 253
- Oncology 407
- Hepatology 74
- Cellular and Molecular Neuroscience 125
Countries citing papers authored by Veronica Finisguerra
This map shows the geographic impact of Veronica Finisguerra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica Finisguerra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica Finisguerra more than expected).
Fields of papers citing papers by Veronica Finisguerra
This network shows the impact of papers produced by Veronica Finisguerra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica Finisguerra. The network helps show where Veronica Finisguerra may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Veronica Finisguerra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2023 | 72 | |
| 3 | 2020 | 92 | |
| 4 | 2019 | 43 | |
| 5 | 2016 | 23 | |
| 6 | MET is required for the recruitment of anti-tumoural neutrophilsbreakdown → | 2015 | 378 |
| 7 | 2013 | 203 | |
| 8 | 2013 | 3 | |
| 9 | 2012 | 94 | |
| 10 | 2011 | 2 | |
| 11 | 2010 | 142 | |
| 12 | 2010 | 106 | |
| 13 | 2008 | 13 |
About Veronica Finisguerra
Veronica Finisguerra is a scholar working on Immunology, Oncology and Hepatology, having authored 13 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (4 papers), Cancer, Hypoxia, and Metabolism (3 papers), Hippo pathway signaling and YAP/TAZ (3 papers), Axon Guidance and Neuronal Signaling (3 papers), Immune cells in cancer (2 papers), Liver physiology and pathology (2 papers), Phagocytosis and Immune Regulation (2 papers) and Cancer-related gene regulation (2 papers). The work is most often cited by research in Immunology (443 citations), Cancer Research (253 citations) and Oncology (407 citations). Veronica Finisguerra has collaborated with scholars based in Belgium, Italy and United Kingdom. Frequent co-authors include Massimiliano Mazzone, Andrea Casazza, Giusy Di Conza, Sofie Deschoemaeker, Hans Prenen, Mathias Wenes, Sarah R. Walmsley, Zvi Granot, Sandra Costa and Mario Di Matteo. Their work appears in journals such as Nature, Journal of Clinical Investigation and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.